N. Kelbick

Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2

M. Caligiuri, M. Grever, J. Byrd, 2004, Clinical Cancer Research.

Quantification of plasma DNA as a prognostic indicator in canine lymphoid neoplasia.

M. Forman, W. Kisseberth, L. Rush, 2007, Veterinary and comparative oncology.

MYC amplification and polysomy 8 in chondrosarcoma: array comparative genomic hybridization, fluorescent in situ hybridization, and association with outcome.

M. Radmacher, C. Morrison, H. Auer, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.

C. Morrison, N. Ramirez, V. Zanagnolo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients

B. Ramaswamy, C. Shapiro, Helen X. Chen, 2006, Clinical Cancer Research.

Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients

B. Ramaswamy, C. Shapiro, Helen X. Chen, 2006, Clinical Cancer Research.

Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis.

C. Morrison, N. Ramirez, J. Pavelka, 2005, American journal of obstetrics and gynecology.

Improved Survival With an Intact DNA Mismatch Repair System in Endometrial Cancer

C. Morrison, W. Frankel, H. Hampel, 2006, Obstetrics and gynecology.

Comparison of bacterial organisms from otic exudate and ear tissue from the middle ear of untreated and enrofloxacin-treated dogs with chronic end-stage otitis

L. Cole, D. Smeak, K. Kwochka, 2004 .